Numero verde: 800-456220

diatermia ad alte frequenze

High frequencies and their therapeutical effects: the studies

Index:

High frequencies and their therapeutical effects: the studies

The controled high frequencies are really so effective?

Our devices are built to provide a practical, fast and effective response in the fields of physiotherapy and vulnology or difficult skin wounds.

Why do we say that they are innovative? Who has measured and analysed the results?

The innovation lies in the devices themselves because of the specific arrangements made in order to generate the controlled high frequencies. Other types of radio frequencies, which exhibit a different behaviour when impact the body, are commonly used in the medical field.

The high frequencies constitute a new, safe and effective alternative to other electromedical devices already on the market. Their biological effects, already present after the first few minutes of treatment, lead to several therapeutical effects, such as:

  • Painkiller effect
  • Anti-inflammatory effect 
  • Myorelaxing effect
  • Anti-edema effect
  • Regenerative effect

Painkilling and myorelaxing effect

ProNexibus Plus®: University of Padua and Verona

Previous
Next

Two independent studies have been conducted by the University of Padua and Verona.

The research group of Prof. Masiero, after 10 sessions of 10-15 minutes, found that the Pronexibus Plus® significantly reduces the pain of several musculoskeletal problems (e.g. osteoarthritis of the knee, neck pain, tendinopathies of the shoulder and of the elbow), moreover, they evidenced as the  patients have been facilitated in the resumption of their daily activities, both working and social.

The research group of Prof. Picelli, University of Verona, used Pronexibus Plus® in patients with sequelae from strokes that no longer responded to treatment with botulinum toxin. The research team found a significant muscle relaxant effect in the short term which remained in the 2 months follow-up period.

Regenerative, anti-edema and anti-inflammatory effects

Rinovacell®: University of Salerno, the RITRALED study

The Rinovacell® was studied by the team of Dr Bruno Luigi Farina of the University of Salerno.

The results were surprising: in patients with chronic diabetic foot ulcers, that is skin lesions that have remained open for over 6 months, the treatment with Rinovacell® allowed the closure of the ulcer. Clinically, the researchers noted a very important reduction of the edema of the foot and a very important anti-inflammatory and antalgic effect: after 1 or 2 therapy sessions the patient’s foot was already deflated and no longer reddened; after 10 sessions the ulcer has closed in almost all cases.

Safety and future perspectives

In all the studies carried out with FocusMed® devices, there were no significant side effects, the therapy was well tolerated by the patients and, indeed, according to the investigators, many patients were positively impressed by the benefits that the therapy gave them.

The University of Verona, very interested in the experimental results obtained with the ProNexibus Plus®, decided to continue the research on our devices in the hope of finding new solutions to increasingly debilitating diseases.

The Rinovacell®, on the other hand, will be used in a double-blind research project in collaboration with the Polyclinic of Abano to deepen the effects of the device in the context of diabetic foot pathology.

Bibliography

Masiero, S. et al. Short-wave diathermy in the clinical management of musculoskeletal disorders: a pilot observational study. Int. J. Biometeorol. (2019) doi:10.1007/s00484-019-01806-x.

Studio RITRALED: Rinovacell® nel trattamento delle lesioni trofiche del piede diabetico, Università di Salerno, Dr Bruno Luigi Farina, 19-21 Settembre 2013, XII Congresso Nazionale AIUC.

ProNexibus Plus® per pazienti con piede equino spastico, Università di Verona, Dr Picelli, 29-30 Novembre 2019, 9° Congresso I.S.Mu.L.T

Related articles

Are you a healthcare practitioner?

Access to the display of products and information material is reserved to operators in the sector in compliance with current legislation. FocusMed Srl requires to qualify as an operator of the sector to proceed with navigation.

Legislative Decree of 24 February 1997, No 46 Article 21

1. It is forbidden to advertise to the public devices that, according to provisions adopted by decree of the Minister of Health, may be sold only on prescription or may be used with the assistance of a doctor or other healthcare professional.
2. Advertising to the public of devices other than those referred to in paragraph 1 is subject to authorization by the Ministry of Health. On the requests for authorization expresses opinion the Commission of experts provided for by article 6, paragraph 3, of the legislative decree 30 December 1992, n. 541, which for this purpose is supplemented by a representative of the Department of the Ministry of Health responsible for medical devices and one of the Ministry of Industry, Commerce and Crafts.